Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 0.42 |
| ▸ | HTR1B | P28222 | 8/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381725 | 0.85 | HTR1D (0.58) | HTR1DHTR1B | |
| SCHEMBL8148201 | 0.85 | ULK1 (0.44) | TTKBRD4AURKA | |
| SCHEMBL8148939 | 0.82 | ULK1 (0.44) | TTKBRD4AURKA | |
| SCHEMBL5309301 | 0.81 | JAK2 (0.53) | HTR1DHTR1BBRD4NPC1RAB9A | |
| SCHEMBL5906358 | 0.78 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5906438 | 0.77 | HTR1D (0.36) | HTR1DHTR1B | |
| SCHEMBL5906442 | 0.77 | HTR1D (0.36) | HTR1DHTR1B | |
| SCHEMBL5302823 | 0.77 | JAK2 (0.43) | PARP1AURKA | |
| SCHEMBL5311332 | 0.77 | JAK2 (0.56) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5311677 | 0.77 | JAK2 (0.55) | HTR1DHTR1BBRD4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841427-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | Pozen, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006081127-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | POZEN INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0978514-B1 | Indazole derivatives as 5-HT1F agonists | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6133290-A | 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000006173-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0978514-A1 | Indazole derivatives as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | HTR1D 13/4885HTR1B 7/4885TTK 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.